Timp2-modified gelatinhydroxyphenylpropionic acid hydrogels reverse enhanced scleral recovery and suppress myopia development in mice
Liu K., Li T., Gu L., Jiang Z., Jiang J., Yang X.
Animal Study, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mater Today Bio (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40677403
- PMCID
- PMC12268941
- DOI
- 10.1016/j.mtbio.2025.101942
- Citations
- 1
Abstract (original English)
A novel therapeutic strategy for form deprivation myopia (FDM) involving Timp2-modified scleral stem cells (SSC Timp2 ) embedded in gelatin-hydroxyphenylpropionic acid (Gtn-HPA) hydrogel was investigated. Transcriptome and single-cell RNA sequencing analyses identified Timp2 as a crucial factor in FDM progression due to its reduced expression in FDM sclera. The developed SSC Timp2 -Gtn-HPA hydrogel composite demonstrated excellent biocompatibility, rapid gelation, and degradation properties. In vitro studies showed that SSC Timp2 -GH promoted human scleral fibroblast (HSF) proliferation, inhibited apoptosis, and prevented differentiation. In vivo experiments in mice showed that SSC Timp2 -GH effectively regulated ocular parameters, facilitated scleral recovery, and improved FDM conditions. These results highlight the potential of SSC Timp2 -GH as a promising therapeutic approach for myopia treatment by enhancing scleral recovery.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.